Eko Health, a SanFrancisco, CA-based company which specializes in applying artificial intelligence for early detection of heart and lung diseases, raised $41M in Series D funding.
Backers included ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, as well as Double Point Ventures, EDBI, and LG Technology Ventures.
The company intends to use the funds to deepen its presence in the U.S. and accelerate its expansion into key international markets. It will also expand access to its AI-enabled cardiac and pulmonary disease detection platform.
Led by CEO Connor Landgraf, Eko Health is a digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, allows them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible.
FinSMEs
05/06/2024